Tyvak International Completes Test Readiness Review of the Milani Nano Satellite
Tyvak International, European leader in small satellite solutions, today announced together with its project partners the successful achievement of Test Readiness Review of the Milani spacecraft. A critical component of the Hera planetary defense mission, Milani will be the European Space Agency’s (ESA) first deep-space nanosatellite. Milani will also be the first nanosatellite ever to orbit an asteroid. Tyvak International is responsible for Milani’s design, build, and mission operations. In this exploration, Tyvak International is joined by an excellent consortium of European industries and research centers from Finland, Czech Republic, and Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231215328597/en/
Milani is a CubeSat developed by Tyvak International SRL, devoted to the visual inspection and dust detection of Didymos asteroid following DART impact. More info under https://tyvak.eu/missions/milani/ (Photo: Business Wire)
As part of the world’s first test of asteroid deflection, following the successful impact of NASA’s DART spacecraft on asteroid Dimorphos, Hera will perform a detailed post-impact survey turning the experiment into a well-understood and repeatable planetary defense technique. To achieve its objectives Hera will be utilizing new technologies from autonomous navigation around an asteroid to low-gravity proximity operations. Hera will be humankind’s first probe to rendezvous with a binary asteroid system and Europe’s flagship Planetary Defender.
Milani, named after Professor Andrea Milani, the pioneer of asteroid risk analysis who came up with the original double-spacecraft Don Quijote mission concept from which the DART-Hera missions were derived, is a companion nanosatellite of Hera, carried by the mothercraft along the journey to Didymos, and ultimately released in its proximity. Milani’s instruments are the ASPECT hyperspectral imager (by VTT, Finland), the VISTA (Volatile In-Situ Thermogravimetre Analyser) dust detector, and the Navigation Camera developed by Tyvak International with the collaboration of Politecnico di Milano for Image Processing algorithms. Finally, laser reflectors (by INFN, Italy) will enable unprecedented gravity field measurements of the asteroid coupled with Hera’s laser range finder.
Tyvak International is part of the Terran Orbital Corporation (NYSE: LLAP) (“Terran Orbital” or the “Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries. “Terran Orbital is proud of Tyvak International’s successful achievement of the Test Readiness Review,” said Terran Orbital Co-Founder, Chairman, and Chief Executive Officer Marc Bell. “We are honored by the trust placed in Tyvak International by ESA, and we look forward to continuing to design, build, deliver, and operate cutting-edge satellite solutions for missions, like Hera Mission.”
“We’ve always been proud to be part of such a challenging mission and the Test Readiness Review is a crucial milestone for the program,” said Tyvak International’s VP of Programs and Milani Program Manager Margherita Cardi. “In the last months we assembled the satellite and saw it taking shape day after day; It was a very exciting and emotional phase for me and the whole team.”
“Admiring the Milani spacecraft fully integrated brings lots of emotions that pay off the tens of thousands of hours of cutting edge engineering efforts,” said ESA Hera Project Manager Ian Carnelli. “Tyvak International has proved unprecedented commitment to bring this project from blueprints to reality, we can’t wait for the environmental test campaign to be completed and start testing with the Hera spacecraft. One step closer to Didymos.”
The next main step for Milani Satellite is the execution of the Environmental Test Campaign at Laboratorio di Qualifica Spaziale of CIRA (Centro Italiano Ricerche Aerospaziali, Capua, Italy), after which it will return to Tyvak for the last tests and verification. Milani will be delivered to ESA in early 2024, to support the Hera electromagnetic compatibility test campaign and extensive System Validation Tests (SVTs), involving the mission ground segment as well.
About Tyvak International
Tyvak International, a Terran Orbital Corporation, is a leading European nano and microsatellite provider, based in Torino, Italy. A front runner in miniaturization and specialized in execution and delivery, Tyvak International is the Prime contractor of European Space Agency for the Milani mission, coordinating a team of 12 entities, universities, research centers, and enterprises in Italy and across all Europe. Learn more at www.tyvak.eu.
About Terran Orbital
Terran Orbital is a leading manufacturer of satellite products primarily serving the aerospace and defense industries. Terran Orbital provides end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of the most demanding military, civil, and commercial customers. Learn more at www.terranorbital.com.
Disclaimer: Please note that the view expressed herein can in no way be taken to reflect the official opinion of the European Space Agency.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231215328597/en/
Contact information
Public Relations
pr@terranorbital.com
949-508-8484
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom